Ebola and global health inequities

Ebola outbreaks continue to pose significant challenges to public health systems worldwide, but recent developments involving a U.S. missionary doctor infected in the Democratic Republic of the Congo (DRC) have sparked discussions about global health disparities. The case of Peter Stafford, a U.S.-based medical worker who contracted Ebola while aiding victims in the DRC, has drawn attention to the stark differences in healthcare infrastructure and resource allocation between high-income countries and regions affected by such outbreaks.

Stafford was evacuated from the DRC in mid-May 2026 for treatment at the Charité – Berlin University Hospital. According to reports, the U.S. government cited proximity as the reason for choosing Germany over the United States for his treatment. However, speculation arose regarding whether the Trump administration might have been reluctant to admit him into the U.S., given its stance on keeping Ebola cases out of the country. A statement from then-Secretary of State Marco Rubio reinforced these concerns, emphasizing efforts to prevent the spread of Ebola within the U.S. borders.

At the Charité, Stafford received an experimental treatment known as MBP-134. This drug is a combination of two monoclonal antibodies derived from a survivor of the 2013 West African Ebola outbreak. These antibodies are produced in laboratories and are part of a broader class of monoclonal antibodies (mAbs) that have gained prominence in modern medicine. While the first mAb was approved in the 1980s for preventing organ rejection after transplants, their use has expanded significantly in the last decade, with approximately 144 mAbs approved by 2025. Among these, lecanemab, used for treating Alzheimer’s disease, has garnered considerable attention.

Despite the promise of MBP-134, its application in Africa remains limited due to logistical and infrastructural constraints. Thomas Cronen, a senior physician and infectious diseases expert at the Charité, highlighted the disparity in healthcare capabilities between Europe and parts of Africa. During a meeting in Nairobi, Kenya, with 50 clinicians from the East African Community (EAC), Cronen discussed the challenges faced in providing adequate care for Ebola patients in low-resource settings. He noted that even within the EAC, healthcare standards vary significantly, with countries like Rwanda offering better facilities compared to others such as South Sudan.

Maximilian Gertler, an epidemiologist and tropical medicine specialist, emphasized that effective treatment requires more than just having the right medication. Proper storage, administration, and monitoring of such drugs necessitate well-equipped medical environments. This highlights a critical issue in global health: while advanced treatments exist, their accessibility in regions with limited healthcare infrastructure remains a major challenge.

The decision to prioritize MBP-134 and another drug, Remdesivir, for experimental treatment during the DRC outbreak came following an emergency meeting held by the World Health Organization (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC). This meeting aimed to address the urgent need for effective interventions in the face of the ongoing crisis. Remdesivir, initially developed for hepatitis C, had previously been tested against COVID-19 during the pandemic, showcasing its versatility as an antiviral agent.

As the situation unfolds, the focus shifts towards understanding the implications of these disparities in healthcare delivery. The case of Peter Stafford underscores the complexities surrounding global health equity, particularly in the context of infectious disease management. As research continues on the effectiveness of drugs like MBP-134 and Remdesivir, the international community faces the challenge of ensuring equitable access to life-saving treatments for all populations affected by such outbreaks.